Apimeds Pharmaceuticals US, Inc
APUSHealthcare|Biotechnology|US
$2.71
-0.03 (-0.92%)
Tangible Book / Share
$65.19
Cash / Share
$0.17
Financials
Financial Snapshot
Market Cap
$4.1M
Enterprise Value
$18.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$58.2M
Cash & Investments
$278.4K
Net Cash
-$14.3M
Free Cash Flow (TTM)
-$13.9M
Operating CF (TTM)
-$13.9M
Debt/Equity
0.14
Cash Runway & Burn Rate
Cash on Hand
$278.4K
Quarterly Burn
$3.5M
Monthly Burn
$1.2M
Est. Runway
~0.1 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $171.4K | $6.2K | $410.5K | $3.5K | $3.6M | $278.4K | |
| Operating Cash Flow | -$823.1K | -$448.2K | -$627.8K | -$733.5K | -$8.9M | -$13.9M | |
| Free Cash Flow | -$823.1K | -$448.2K | -$627.8K | -$733.5K | -$9.0M | -$13.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$57.3K | -$53.4K | |
| Financing Cash Flow | $400.0K | $282.9K | $1.0M | $326.5K | $20.6M | $13.5M |
R&D Spending
R&D (TTM)
$2.8M
R&D Intensity
—
R&D Growth vs Prior
+74.1%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $489.9K | $368.0K | $98.5K | $0.00 | $1.6M | $2.8M | |
| SG&A | $529.6K | $271.5K | $648.9K | $1.3M | $10.3M | $24.5M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $5.7K | $20.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$5.7K | -$20.0K | |
| R&D | $489.9K | $368.0K | $98.5K | $0.00 | $1.6M | $2.8M | |
| SG&A | $529.6K | $271.5K | $648.9K | $1.3M | $10.3M | $24.5M | |
| Operating Income | -$1.0M | -$639.5K | -$747.4K | -$1.3M | -$11.9M | -$19.2M | |
| Interest Expense | $6.7K | $29.1K | $38.1K | $117.7K | $283.0K | $4.3M | |
| Pretax Income | -$1.0M | -$668.7K | -$777.7K | -$1.4M | -$6.0M | -$58.2M | |
| Net Income | -$1.0M | -$668.7K | -$777.7K | -$1.4M | -$6.0M | -$58.2M | |
| EPS (Diluted) | -8.08 | -5.27 | -6.13 | -11.00 | -5.50 | -49.29 | |
| EBITDA | -$1.0M | -$639.5K | -$739.6K | -$1.3M | -$5.7M | -$53.8M | |
| Shares Out. (M) | 0.13 | 0.13 | 0.13 | 0.13 | 1.09 | 1.63 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $171.4K | $6.2K | $410.5K | $3.5K | $1.6M | $278.4K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $0.00 | |
| Total Current Assets | $172.2K | $6.2K | $422.1K | $13.1K | $14.0M | $10.7M | |
| Total Assets | $172.2K | $6.2K | $422.1K | $13.1K | $164.2M | $127.6M | |
| Total Current Liabilities | $10.7K | $319.8K | $123.3K | $1.0M | $10.7M | $21.1M | |
| Long-Term Debt | $400.0K | $400.0K | $266.9K | $346.8K | $0.00 | $101.9K | |
| Total Liabilities | $410.7K | $719.8K | $390.2K | $1.4M | $10.8M | $21.2M | |
| Stockholders' Equity | -$238.5K | -$713.6K | $31.9K | -$1.4M | $153.3M | $106.4M | |
| Retained Earnings | -$1.6M | -$2.2M | -$3.0M | -$4.4M | -$10.4M | -$65.6M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$823.1K | -$448.2K | -$627.8K | -$733.5K | -$8.9M | -$13.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$57.3K | -$53.4K | |
| Free Cash Flow | -$823.1K | -$448.2K | -$627.8K | -$733.5K | -$9.0M | -$13.9M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | -$10.1M | -$8.1M | |
| Financing Cash Flow | $400.0K | $282.9K | $1.0M | $326.5K | $20.6M | $13.5M | |
| Issuance of Stock | $0.00 | $0.00 | $1.1M | $0.00 | $11.6M | -$323.3K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $400.0K | $260.0K | $0.00 | $250.0K | $9.3M | $14.0M | |
| Stock Based Comp. | $193.5K | $193.5K | $70.0K | $0.00 | $0.00 | $42.7K | |
| Net Change in Cash | -$423.1K | -$165.3K | $404.3K | -$407.0K | $9.6M | -$457.0K |
Dilution Tracker
Shares outstanding grew 757.3% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+757.3%
Stock Issuance (TTM)
-$323.3K
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.13 | 0.13 | 0.13 | 0.13 | 1.09 | 1.63 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 757.3% | 50.0% | |
| Stock Issuance | $0.00 | $0.00 | $1.1M | $0.00 | $11.6M | -$323.3K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $193.5K | $193.5K | $70.0K | $0.00 | $0.00 | $42.7K |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 430.3% | 93.7% | -2440.1% | 102.3% | -3.9% | -59.0% | |
| ROA % | -596.1% | -10835.6% | -184.3% | -10645.6% | -3.7% | -45.6% | |
| ROIC % | -631.2% | 1193.0% | -250.2% | 167.5% | -7.4% | -15.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 37.3% | -16.9% | -70.6% | -834.2% | |
| Net Income | 0.0% | 34.8% | -16.3% | -78.7% | -331.7% | |
| EPS (Diluted) | 0.0% | 34.8% | -16.3% | -79.4% | 50.0% | |
| Operating Cash Flow | 0.0% | 45.6% | -40.1% | -16.8% | -1116.8% | |
| Free Cash Flow | 0.0% | 45.6% | -40.1% | -16.8% | -1124.6% | |
| R&D Expense | 0.0% | -24.9% | -73.2% | -100.0% | 0.0% | |
| SG&A Expense | 0.0% | -48.7% | 139.0% | 96.5% | 705.8% | |
| Total Assets | 0.0% | -96.4% | 6739.7% | -96.9% | 1257338.4% | |
| Book Value / Share | 0.0% | -199.2% | 104.5% | -4361.3% | 1296.0% | |
| Debt | 0.0% | 65.0% | -59.6% | 123.6% | 1200.2% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 757.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.04
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$65.19
Cash / Share
$0.17
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.47 | -3.79 | -3.26 | -1.83 | -2.98 | -0.05 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -10.63 | -3.55 | 79.57 | -1.87 | 0.12 | 0.04 | |
| EV/EBITDA | -2.71 | -4.99 | -3.23 | -2.46 | -4.20 | -0.34 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-2.09
Distress
Piotroski F-Score
1
Weak